Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2006

View Archived Issues

rhIL-11 induces sTNFRI shedding, alleviates chemotherapy-induced mucositis

Novel approach to cancer immunotherapy with genetically engineered lymphocytes

Ghrelin analogue shows efficacy for CHF-associated cardiac cachexia

A2A receptor antagonists come forth as potential cancer immunotherapeutics

High-dose rNAPc2 improves ischemia in patients with NSTE-ACS

Salix licenses U.S. rights to Sanvar IR

Enrollment completed in phase II/III study of MN-001 in interstitial cystitis

NicOx provides full update on status of lead programs and collaborations

Clolar studied in older patients with AML

Xanthus licenses targeted cancer compounds from Schering

LX-6171 for cognitive disorders begins phase I study

Phase II trial studies CDA-1 and MDX-1388 in C. difficile associated diarrhea

GSK reports on a novel candidate for histamine H3 antagonism in AD

Phase II study evaluates R-788 for rheumatoid arthritis

Israeli approval for phase II study of CF-101 in keratoconjunctivitis sicca

Abuse resistant drug ELI-216 studied in phase II

Astellas profiles new promising agent to enhance bisphosphonate therapy in osteoporosis

AlphaVax reports phase I findings for HIV vaccine

Anthera licenses antiinflammatory compounds from Lilly and Shionogi

Dynavax and AstraZeneca collaborate on TLR-9 agonists for asthma and COPD

Laquinimod reduces rate of inflammatory disease activity in MS patients

Novel therapeutic strategies for metabolic disorders described in recent patents

Novel therapeutic agents for asthma described in recent patents

Scripps patent discloses novel transthyretin amyloid inhibitors for amyloidosis

Abbott seeks approval for Humira in Crohn's disease in U.S. and E.U.

Plavix approved in Europe for patients with STEMI

Sanofi-aventis withdraws dronedarone MAA with plans to resubmit

Takeda discontinues development of TAK-654 for diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...